Advisory for the Prevention and Control of Diphtheria

Objectives

The advisory seeks to prevent, identify and control diphtheria during winter by maintaining professional vigilance for a vaccine-preventable infection that is mainly transmitted through respiratory droplets.[1]It focuses on improving vaccination coverage and reinforcing infection prevention and control across healthcare and community settings.[1]The extract does not set out a wider formal strategic framework, long-term mission statement or quantified goals beyond these operational priorities.[2]

• Enhance routine immunisation coverage, recognising that incomplete vaccination is associated with diphtheria outbreaks.[1]
• Strengthen infection prevention and control in hospitals and communities, particularly where overcrowding, poor hygiene and malnutrition may contribute to outbreak risk.[1]
• Maintain vigilance among health professionals to detect suspected cases promptly and implement prevention and control measures.[1]
• Promote three 0.5 millilitre intramuscular doses of diphtheria, pertussis and tetanus vaccine at six, ten and fourteen weeks of age.[3]
• Encourage hand hygiene, respiratory etiquette and standard precautions in patient-care and community environments.[3]
• Protect people at elevated risk of exposure by advising suspected cases to avoid contact with young children and women in late pregnancy, especially if they are unimmunised, until antibiotics have been taken for at least two days.[2]

Implementation

The delivery approach combines clinical case management, laboratory testing, surveillance-triggered public-health action, routine immunisation and broad institutional dissemination.[3][4]It assigns a specific stockpiling responsibility for diphtheria antitoxin to the Drug Regulatory Authority of Pakistan (DRAP), while involving surveillance units, health authorities, hospitals, immunisation coordinators and public, military, private and specialised healthcare institutions.[3][4]The extract does not specify a formal governance hierarchy, implementation timetable, budget, funding source, monitoring indicators or performance targets.[2][4]

• Isolate patients in single rooms and apply standard precautions, supplemented by droplet precautions for respiratory disease and contact precautions for cutaneous disease.[3]
• Administer diphtheria antitoxin immediately to probable respiratory cases on clinical grounds, without waiting for laboratory confirmation.[3]
• Use recommended antibiotics, including azithromycin, clarithromycin, erythromycin and penicillin, and use trimethoprim-sulfamethoxazole where appropriate.[3]
• Provide prophylactic therapy to unimmunised contacts before culture results are available.[3]
• Collect nasopharyngeal specimens for culture or polymerase chain reaction using sterile polyester, rayon or nylon-flocked swabs; place specimens in Amies transport medium with charcoal; and transport them at 2 to 8 degrees Celsius within 24 to 48 hours.[3]
• Use polymerase chain reaction as a rapid and more sensitive test, while retaining culture as the gold-standard laboratory test.[3]
• Identify suspected or probable cases as upper-respiratory illness with an adherent membrane affecting the tonsils, pharynx, larynx or nose; confirm cases through culture isolation of Corynebacterium species.[3]
• Recognise epidemiologically linked cases where a suspected case had intimate respiratory or physical contact with a laboratory-confirmed case during the 14 days before sore-throat onset.[3]
• Trigger a public-health response following one laboratory-confirmed case, and investigate immediately when two epidemiologically linked cases, including at least one laboratory-confirmed case, meet the outbreak definition using case-based data.[3]
• Maintain diphtheria antitoxin stockpiles, with the required size dependent on diagnostic capacity and healthcare-service provision; ensure minimum required stockpiles through DRAP.[3]
• Apply droplet and contact precautions in patient settings and at community level, and promote covering the mouth and nose when coughing or sneezing.[2]
• Distribute the advisory to federal, provincial, territorial and district health bodies; public-sector, military, private and specialised healthcare institutions; healthcare commissions; hospitals; and immunisation coordinators.[2][4]
• Engage the Federal Disease Surveillance Unit at the National Institutes of Health and Provincial Disease Surveillance Units within provincial health directorates in dissemination and surveillance-related coordination.[4]

Monitoring & Evaluation

Monitoring and public-health action focus on early clinical recognition, laboratory confirmation, case classification and immediate investigation of defined transmission events. The extract does not specify routine monitoring indicators, reporting formats, performance targets, evaluation methods or a formal accountability framework.[3][2][4]

• Detect suspected diphtheria through the specified clinical presentation of upper-respiratory illness with an adherent membrane involving the tonsils, pharynx, larynx or nose.[3]
• Confirm cases by culture-based isolation of Corynebacterium species; culture is identified as the gold-standard laboratory test.[3]
• Use polymerase chain reaction as a rapid and more sensitive diagnostic test alongside culture.[3]
• Collect nasopharyngeal specimens using sterile polyester, rayon or nylon-flocked swabs, place them in Amies transport medium with charcoal, and transport them at 2–8 °C within 24–48 hours.[3]
• Classify epidemiologically linked cases where a suspected case has had intimate respiratory or physical contact with a laboratory-confirmed case during the 14 days before sore-throat onset.[3]
• Trigger a public-health response after one laboratory-confirmed case.[3]
• Investigate an outbreak immediately using case-based data when two epidemiologically linked cases are identified, including at least one laboratory-confirmed case.[3]
• Maintain surveillance-system involvement through the Federal Disease Surveillance Unit at the National Institutes of Health and Provincial Disease Surveillance Units within provincial health directorates.[4]
• Distribute the advisory to federal, provincial, territorial and district authorities, public-sector, military, private and specialised healthcare institutions, healthcare commissions, hospitals, health departments and immunisation coordinators.[2][4]
• Apply infection-prevention measures that support case containment, including standard precautions, droplet precautions for respiratory disease, contact precautions for cutaneous disease, isolation of patients in single rooms, hand hygiene and respiratory etiquette.[3]
• Advise suspected cases to avoid contact with young children and women in late pregnancy, particularly people who are unimmunised, until antibiotic treatment has been taken for at least two days.[2]

Costing & Financing

No budget, costed allocation, funding source, resource-mobilisation mechanism, funding gap or economic assumption is specified. The only explicit resource requirement is the maintenance of diphtheria antitoxin stockpiles, for which the source provides no monetary value or quantity.[3][2][4]

• Maintain diphtheria antitoxin stockpiles as a preparedness resource for probable respiratory cases, for whom antitoxin should be administered immediately on clinical grounds.[3]
• Determine the appropriate stockpile size in relation to diagnostic capacity and healthcare-service provision.[3]
• Assign responsibility to the Drug Regulatory Authority of Pakistan (DRAP) for ensuring minimum required antitoxin stockpiles.[3]
• Provide routine prevention through three 0.5 ml intramuscular diphtheria, pertussis and tetanus (DPT) doses at six, ten and fourteen weeks of age, although the extract gives no vaccine procurement, delivery or programme-cost information.[3]
• Provide antibiotic prophylaxis to contacts who are not immunised before culture results are available, without specifying the associated medicine, laboratory or service-delivery costs.[3]